NAFDAC alerts public of fake anti-hypertension drug

NAFDAC Office
National Agency for Food and Drug Administration and Control (NAFDAC) headquarters

The National Agency for Food, Drug Administration and Control (NAFDAC) has alerted the public of the circulation of a fake anti-hypertensive drug.

Moji Adeyeye, NAFDAC’s Director General (DG), in a statement on Tuesday in Abuja, said the drug, Hydrochlorothiazide 50mg (containing Glibenclamide) was currently circulating in Cameroon.

“NAFDAC is alerting the public, especially healthcare providers on the circulation of confirmed falsified Hydrochlorothiazide 50mg tablets in Cameroun.

“The falsified product has been found to contain Glibenclamide instead of Hydrochlorothiazide.

“In March 2019, the World Health Organisation (WHO) was informed by an NGO in Cameroun that a medicine, presented as Hydrochlorothiazide 50mg tablets, has caused hypoglycaemia in patients.

“Confirmatory laboratory analysis has established that the product did not contain hydrochlorothiazide, the stated active ingredient, glibenclamide was instead identified,” Adeyeye said.

She explained that the genuine version of the drug was for treatment of hypertension.

According to her, the falsified medicine poses grave danger to patients.

“Hydrochlorothiazide is used as an anti-hypertensive and diuretic medicine, whereas Glibenclamide is an anti-diabetic medicine.

“The falsified medicine presents a risk for patients who are taking hydrochlorothiazide for the treatment of hypertension.

“The label on the plastic container of this falsified product states Laboratoires Sterop as the manufacturer, however, this company has confirmed to WHO that it did not manufacture or supply the falsified product.

“The Falsified hydrochlorothiazide 50mg is presented in plastic containers of 1000 tablets each,” she said.

The NAFDAC DG further said the drug which had a batch number of 16G04, also carried 16/2017 as its Manufacture Date and 30/05/2021 as Expiry Date.

“The batch number, as well as a number of other features shown on the label of the falsified Hydrochlorothiazide 50mg tablets, do not correspond with genuine manufacturing records. The label is English and French languages.

She advised importers, wholesalers, and retailers to avoid illegal importation and sale of the drug in Nigeria as surveillance had been heightened to prevent such.

“Surveillance has been strengthened by NAFDAC at all ports of entry to prevent importation of the falsified Hydrochlorothiazide 50mg tablets from Cameroon.

“NAGDAC has also heightened surveillance to prevent distribution and sale of the falsified product.

“Healthcare providers and other members of the public are advised to be vigilant and contact the nearest NAFDAC office with any information on the product,” she said.

Mrs Adeyeye further advised those already in possession of the drug to submit it to the nearest NAFDAC office.

She advised consumers to report any adverse effects related to the use of medicines to the nearest NAFDAC office, its Toll Free number 20543, to all Networks, or via its e-mail pharmacovigilance@nafdac.gov.ng.

(NAN)

Support PREMIUM TIMES' journalism of integrity and credibility

 

Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.

For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.

By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.

Donate


NEVER MISS A THING AGAIN! Subscribe to our newsletter

* indicates required

DOWNLOAD THE PREMIUM TIMES MOBILE APP

Now available on

  Premium Times Android mobile applicationPremium Times iOS mobile applicationPremium Times blackberry mobile applicationPremium Times windows mobile application

TEXT AD: This space is available for a Text_Ad.. Call Willie on +2347088095401 for more information


All rights reserved. This material and any other material on this platform may not be reproduced, published, broadcast, written or distributed in full or in part, without written permission from PREMIUM TIMES.